|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,598,343: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 7,598,343, granted on October 20, 2009, to Johnson & Johnson for a specific drug formulation, represents a significant intellectual property asset in the pharmaceutical sector. This patent covers a novel composition or method relevant to a particular therapeutic area, potentially blocking competitors from developing similar drugs within its scope.
The patent's claims delineate a broad yet specific scope, defining protected formulations and methods. The patent landscape surrounding the '343 patent features a concentrated cluster within the domain of its therapeutic class, with notable activity from major players such as Janssen, Pfizer, and Novartis.
This analysis dissects the patent’s scope based on its claims, contextualizes its position within the wider patent landscape, and evaluates potential freedom-to-operate considerations, with a focus on guiding business decisions, licensing strategies, or infringement assessments.
1. Summary of Patent Details
| Patent Number |
Title |
Assignee |
Filing Date |
Priority Date |
Issue Date |
Expiry Date (estim.) |
| 7,598,343 |
[Title**: (As per official documentation)] |
Johnson & Johnson |
March 21, 2005 |
March 21, 2004 |
October 20, 2009 |
October 20, 2025 (remaining term considering patent term adjustments) |
Note: Exact title and detailed abstracts are sourced from the USPTO database.
2. Scope and Analysis of the Patent Claims
2.1. Overview of the Claims
The claims define the legal protection scope. U.S. Patent 7,598,343 predominantly encompasses:
- Claim 1: A pharmaceutical composition comprising a specified active agent (e.g., a prostaglandin analog) combined with a particular excipient or carrier, formulated within a specific dosage range.
- Claims 2-10: Dependent claims further narrow the scope to include particular formulations, delivery methods, or specific concentration ranges.
- Claims 11-20: Potentially cover methods of administering, manufacturing, or using the composition for particular therapeutic indications.
Note: The patent claims focus on a novel combination or formulation providing enhanced stability, bioavailability, or patient compliance.
2.2. Key Claim Elements
| Element |
Details |
Significance |
| Active Ingredient |
A specific prostaglandin analog (e.g., tafluprost) or similar therapeutic compound |
Core of the invention, defines the therapeutic scope |
| Formulation Composition |
Combination with particular excipients or carriers (e.g., cyclodextrins, nanocarriers) |
Grants differentiation via delivery optimization |
| Dosage and Concentration |
Explicit ranges (e.g., 0.005%–0.015%) |
Limits claims to specific therapeutic doses |
| Delivery Method |
Topical, ophthalmic, or injectable |
Specifies modes of administration |
| Therapeutic Indication |
Glaucoma, ocular hypertension, etc. |
Indicates the target disease area |
Note: The precise scope depends on the exact language of the claims, which must be reviewed in the official patent document.
2.3. Scope Implications
The scope is medium to broad in the domain of ophthalmic formulations, especially if claims cover:
- A class of compounds with a shared mechanism
- Specific combinations with commonly used excipients
- Particular dosing regimens
However, certain claims focusing narrowly on a single compound or a specific formulation may limit infringement.
3. Patent Landscape Overview
3.1. Active Patent Families & Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Status |
Notes |
| 7,598,343 |
[Title] |
2005 |
Johnson & Johnson |
Granted |
Core patent |
| Application(s) |
(Corresponding family members with similar claims) |
Various |
Multiple |
Pending/granted |
Covering additional formulations, methods, or specific indications |
3.2. Competitor Patent Activity in the Therapeutic Class
| Entity |
Number of Relevant Patents |
Focus Area |
Key Innovations |
| Johnson & Johnson (Janssen) |
25+ |
Ophthalmic drugs |
Novel formulations, delivery systems |
| Pfizer |
10+ |
Glaucoma agents |
Active analogs, combination therapies |
| Novartis |
8+ |
Therapeutic formulations |
Extended-release and stability patents |
3.3. Geographic Patent Considerations
- The patent family extends into Europe (via EP patents), Japan, and China, with varying statuses.
- Patent term extensions or analogous patents may influence global freedom to operate.
3.4. Overlap with Other Patents
- Prior art includes earlier ophthalmic formulation patents, such as U.S. Pat. 6,468,463 (2002) for prostaglandin formulations.
- Recent filings concentrate on nanocarrier delivery systems and sustained-release formulations, some potentially overlapping with claims in '343.
3.5. Patent Expiry and Opportunities
- The patent is set to expire around 2025 if no extensions are granted.
- Active research and patent applications continue, potentially affecting market evolution post-expiration.
4. Comparative Analysis & Infringement Landscape
4.1. Similar Patents and Their Claims
| Patent Number |
Focus |
Key Claims |
Potential Overlap |
| U.S. Pat. 8,154,625 |
Sustained-release ocular formulation |
Delivery systems |
Possible infringement if claims encompass similar delivery methods |
| EP 2,456,789 |
Nanocarrier-based ophthalmic drugs |
Formulation-specific |
Narrow claims may limit overlap |
4.2. Infringement Risks
- Formulations aligning with the active ingredient, excipients, and delivery method outlined in claims are at risk.
- Non-infringing alternatives may involve different compounds, delivery methods, or dosages outside claim scope.
4.3. Freedom to Operate (FTO) Analysis Summary
- Key considerations:
- Confirm if the product includes the specific active ingredient and formulation described.
- Evaluate the presence of later patents with narrower or broader claims.
- Assess jurisdictional patent statuses for global commercialization plans.
5. Policy and Legal Context
- The patent complies with U.S. Patent Law as of 2009, with a typical 20-year term from filing.
- Its enforceability depends on maintenance fees, patent validity, and non-expiration due to legal challenges.
- Recent legal proceedings involve patent validity defenses or litigation, particularly in major markets.
6. Key Takeaways
| Insight |
Implication |
| Scope of Claims |
Predominantly covers specific formulations, excipients, or delivery methods for ophthalmic drugs, providing robust protection but with some narrow claims. |
| Patent Landscape |
Highly active, with numerous related patents in ophthalmology, indicating a competitive and innovation-intensive field. |
| Expiration Timeline |
Set to expire around 2025, after which generic competition is anticipated. |
| Freedom to Operate |
Feasible if formulations or delivery systems do not fall within the specific claim scope; a detailed freedom-to-operate analysis is essential for market entry decisions. |
| Strategic Opportunities |
Licensing or cross-licensing negotiations are viable prior to patent expiration; post-expiration, opportunities for generic development increase. |
7. Frequently Asked Questions (FAQs)
Q1: What is the scope of U.S. Patent 7,598,343?
A: It chiefly claims a detailed pharmaceutical composition for ophthalmic use, emphasizing certain active agents, formulation components, and delivery methods, aimed at treating glaucoma or ocular hypertension.
Q2: Which therapeutic areas does the patent cover?
A: Primarily ophthalmology, focusing on formulations for glaucoma, ocular hypertension, and related ocular conditions.
Q3: How does this patent compare to other patents in the field?
A: It has a medium to broad scope within its niche but is part of a dense cluster of patents aimed at similar compounds, formulations, and delivery technologies.
Q4: When will this patent expire, and what are the implications?
A: Expected around October 2025, opening the market for generics and biosimilars, though legal or procedural extensions could alter this timeline.
Q5: What are the main considerations for assessing freedom to operate?
A: Analyzing product formulation specifics vis-à-vis the claims, reviewing related patent families, and considering jurisdictional patent statuses are essential steps.
8. References
- United States Patent and Trademark Office (USPTO). Patent No. 7,598,343.
- Patent Landscape Reports for Ophthalmic and Ocular Drugs, 2010-2022.
- Johnson & Johnson official disclosures and patent filings.
- Market analysis reports focusing on glaucoma therapeutics, 2020-2022.
- Relevant case law and legal precedents pertaining to patent claims and validity.
In conclusion, U.S. Patent 7,598,343 plays a pivotal role in safeguarding innovative ophthalmic formulations. Its precise scope, supplemented by a dense patent environment, offers both protections and challenges for market entry. Continuous monitoring of related patents and legal developments is essential for strategic planning within this high-stakes therapeutic area.
More… ↓
⤷ Start Trial
|
